The strong operating beat is overshadowed by the $150M shelf filed 12 days ago — the company is signaling it will need capital to fund growth and FDA/CE market entry. Watch for a takedown announcement under the shelf in the coming weeks; any offering below $3.00/share (the March PIPE price) would be a negative signal. The stock may gap up on the revenue beat but the shelf overhang limits upside.
Price Chart
Executive Summary
SS Innovations reported record Q1 2026 revenue of $11.1M, up 116.8% YoY, driven by strong SSi Mantra system installations and procedure growth. Gross margin expanded to 48.0% from 21.2% a year ago, and net loss narrowed to $3.6M from $5.7M. However, the company filed a $150M universal shelf registration 12 days prior, signaling potential future dilution that tempers the positive operating momentum.
Key Financial Metrics
Key Facts
- Record Q1 2026 revenue of $11.1M, up 116.8% from $5.1M in Q1 2025
- Gross margin expanded to 48.0% from 21.2% YoY
- Gross profit rose 390.0% to $5.3M from $1.1M
- Net loss narrowed to $3.6M ($0.02/diluted share) from $5.7M ($0.03/diluted share)
- SSi Mantra installations totaled 26, up 73.3% from 15 in Q1 2025
- Cash and cash equivalents of $16.0M, up from $3.2M at year-end 2025
- Filed $150M universal shelf registration (S-3) on May 1, 2026 — 12 days prior to this earnings release
- Completed $18.6M private placement in March 2026 at $3.00-$4.00/share
- No long-term debt; operating cash burn improved to $2.3M from $6.1M in Q1 2025
- FDA 510(k) review for SSi Mantra expected by mid-2026; CE marking pathway ongoing
Financial Impact
Revenue growth of 116.8% YoY to $11.1M; net loss improved to $3.6M from $5.7M; gross margin expanded to 48.0% from 21.2%
Risk Factors
- Potential dilutive offering under the $150M shelf registration filed May 1, 2026
- Still unprofitable with cumulative deficit of $59.4M; operating cash flow negative $2.3M in Q1
- FDA 510(k) clearance for SSi Mantra not yet obtained; any delay or denial would be a major setback
- Accounts receivable of $21.3M (current + non-current) vs $11.1M quarterly revenue suggests collection risk
- Foreign currency translation loss of $1.6M in Q1 adds volatility to reported results
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-055468 |
| Document: ea0290453-8k_ssinnovations.htm | 0001213900-26-055468 |
| Document: 0001213900-26-055468-index-headers.html | 0001213900-26-055468 |
| Document: 0001213900-26-055468-index.html | 0001213900-26-055468 |
| Document: 0001213900-26-055468.txt | 0001213900-26-055468 |
| 8-K Data (Synthetic) | 0001213900-26-055468 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+5 | — | — |
Oct 26, 2026 today | Press Release | — | awaiting T+5 | — | — |
Oct 13, 2026 13d ago | 8-K | $2.55 $2.54 | ▼ −0.39% | ▲ +0.76% | $2.37 (−7.06%) |
Oct 13, 2026 13d ago | 8-K | $2.55 $2.54 | ▲ +0.39% | ▼ −0.76% | $2.37 (+7.06%) |
Oct 9, 2026 17d ago | 424B5 | $2.55 $2.45 | ▲ +3.92% | ▲ +2.43% | $2.37 (+7.06%) |
Oct 5, 2026 21d ago | 8-K | $2.77 $2.55 | ▼ −7.94% | ▼ −8.36% | $2.37 (−14.44%) |
Sep 10, 2026 6w ago | 8-K | $3.30 $3.26 | ▼ −1.21% | ▼ −0.71% | $2.37 (−28.18%) |
Aug 13, 2026 10w ago | 8-K | $3.83 $3.61 | ▼ −5.74% | ▼ −3.78% | $2.37 (−38.12%) |
Jul 17, 2026 14w ago | 8-K | $3.64 $3.57 | ▼ −1.92% | ▼ −1.24% | $2.37 (−34.89%) |
Jul 14, 2026 14w ago | 8-K | $3.67 $3.75 | ▲ +2.18% | ▲ +3.48% | $2.37 (−35.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers